Cost analysis of adverse events associated with non-small cell lung cancer management in France.

about

Immunotherapy "Shock" a case series of PD-L1 100% and pembrolizumab first-line treatment.

P2860

Q41563422-9BAE0305-9F7C-46AE-9CC7-367D5BE48B30

P2860

Cost analysis of adverse events associated with non-small cell lung cancer management in France.

Item

http://www.wikidata.org/entity/Q38631475

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Cost analysis of adverse event ...... g cancer management in France.

@en

type

Item

label

Cost analysis of adverse event ...... g cancer management in France.

@en

prefLabel

Cost analysis of adverse event ...... g cancer management in France.

@en

P1476

Cost analysis of adverse event ...... g cancer management in France.

@en

P2093

Amira Fannan

http://www.w3.org/2001/XMLSchema#string

Aurélie Millier

http://www.w3.org/2001/XMLSchema#string

Chloé Godard

http://www.w3.org/2001/XMLSchema#string

Delphine Loirat

http://www.w3.org/2001/XMLSchema#string

Emilie Clay

http://www.w3.org/2001/XMLSchema#string

Laurie Lévy-Bachelot

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness and safety of pemetrexed versus docetaxel as a treatment for advanced non-small cell lung cancer: a systematic review and meta-analysis

Erlotinib in previously treated non-small-cell lung cancer

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Epidemiology of lung cancer prognosis: quantity and quality of life.

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.

Economic burden of toxicities associated with treating metastatic melanoma in eight countries.

Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy.

P304

443-449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CEOR.S138963

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Eric Angevin

Christos Chouaid

P577

2017-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28794648

http://www.w3.org/2001/XMLSchema#string

P932

5538537

http://www.w3.org/2001/XMLSchema#string

Cost analysis of adverse events associated with non-small cell lung cancer management in France.

about

P2860

P2860

Cost analysis of adverse events associated with non-small cell lung cancer management in France.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P932